Naeimi Reza, Najafi Rezvan, Molaei Pejman, Amini Razieh, Pecic Stevan
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Eur J Pharmacol. 2022 Dec 5;936:175350. doi: 10.1016/j.ejphar.2022.175350. Epub 2022 Oct 25.
Colorectal cancer (CRC) is one of the most challenging malignancies in terms of diagnosis and treatment. Conventional diagnostic methods are primarily based on colonoscopy and often lack accuracy, while standard treatment options typically include chemotherapy, which can be unsuccessful due to side effects and (development of) drug resistance. Although new diagnostic methods and timely screening have decreased the death rate from cancer in developed countries in recent years, there still is an urgent need for (novel) therapeutic strategies that render better disease management and clinical outcomes. Nanoparticles (NPs) have emerged as promising candidates for the improvement of diagnosis and treatment by promoting drug targeting, solubility and bioavailability. For example, NPs can reduce toxicity of drugs by increasing solubility and can be engineered to specifically target malignancies, thereby minimizing unwanted side effects. In this review, we evaluated the potential of implementing various NPs for the diagnosis and treatment of CRC.
结直肠癌(CRC)在诊断和治疗方面是最具挑战性的恶性肿瘤之一。传统的诊断方法主要基于结肠镜检查,且常常缺乏准确性,而标准的治疗选择通常包括化疗,但由于副作用和耐药性,化疗可能并不成功。尽管近年来新的诊断方法和及时的筛查降低了发达国家的癌症死亡率,但仍迫切需要能够实现更好的疾病管理和临床结果的(新型)治疗策略。纳米颗粒(NPs)已成为通过促进药物靶向性、溶解性和生物利用度来改善诊断和治疗的有前景的候选物。例如,纳米颗粒可以通过增加溶解度来降低药物毒性,并且可以设计成特异性靶向恶性肿瘤,从而将不良副作用降至最低。在本综述中,我们评估了应用各种纳米颗粒诊断和治疗结直肠癌的潜力。